m+Medelevator.RU
← Поиск публикаций
Frontiers in aging neuroscience · 2026

Multimodal data-driven eye-movement subtypes and their cerebral glucose metabolic patterns in Parkinson's disease.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Zhang Yifan, Zhang Wenli, Li Guoyang, Huang Jing, Zou Huahui, Zhang Xucheng, Wang Xiangcheng, Luo Xiaoguang

Аннотация

BACKGROUND: Previously reported Parkinson's disease (PD) subtyping schemes often show limited stability and cross-cohort generalizability.

OBJECTIVE: To derive data-driven oculomotor subtypes in PD using multi-task eye-movement assessment and to characterize their cerebral glucose metabolic patterns.

METHODS: We administered a non-invasive multi-task eye-movement battery to 122 patients with PD and 69 healthy controls. Multidimensional oculomotor features were analyzed using unsupervised k-means clustering to identify PD subtypes. In a PD subset undergoing 18F-fluorodeoxyglucose positron emission tomography (FDG-PET; n = 30), regional cerebral glucose metabolism was quantified to compare metabolic profiles between subtypes.

RESULTS: Clustering identified two PD subtypes: an oculomotor-efficient subtype (PD-E) and an oculomotor-inefficient subtype (PD-I). The subtypes differed across multiple oculomotor parameters, with antisaccade (AS) metrics showing the most prominent divergence. Compared with PD-I, PD-E showed higher FDG uptake in frontotemporal cortices. Metabolic differences were directionally concordant with groupwise patterns in cognitive measures.

CONCLUSION: Integrating eye-movement digital phenotypes with FDG-PET metabolism may provide complementary information for cognitive-domain profiling and assessment in PD. Longitudinal studies and independent cohort validation are needed to confirm stability and clinical translatability.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты